{"id":"W2049420921","doi":"10.1007/s00192-013-2161-4","title":"What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder?","year":2013,"lang":"en","type":"review","venue":"International Urogynecology Journal","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Mirabegron; Overactive bladder; Medicine; Tolterodine; Tolerability; Adverse effect; Solifenacin; Oxybutynin; Intensive care medicine; Urology; Internal medicine; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00101552,0.000593629,0.002707726,0.001703873,0.0003331492,0.001359671,0.001256935,0.00153079,0.00314781],"category_scores_gemma":[0.001860995,0.0004026243,0.000974462,0.002051855,0.0005701108,0.001963849,0.0005071053,0.001987324,0.001062616],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005073326,"about_ca_system_score_gemma":0.001358771,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002431045,"about_ca_topic_score_gemma":0.006321465,"domain_scores_codex":[0.9997433,0.00005145225,0.00005837843,0.0000436757,0.000082175,0.00002099456],"domain_scores_gemma":[0.9989741,0.000639636,0.0001670102,0.00001322337,0.0001567797,0.00004930408],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002352934,0.00008168262,0.0003197452,0.04235201,0.0004174859,0.0002270345,0.00008740371,0.0002372083,0.0008200955,0.001322792,0.02094565,0.9329535],"study_design_scores_gemma":[0.0002695525,0.0004797609,0.002926047,0.03402152,0.002053725,0.003132267,0.0003351602,0.0003179902,0.0007644694,0.002344755,0.9532714,0.00008332876],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0000842728,0.9991862,0.00003209929,0.0003973985,0.00009725166,0.000002017297,0.00001227107,0.000001904967,0.000186567],"genre_scores_gemma":[0.0004542783,0.9989198,0.00006852843,0.0003082831,0.0001313475,0.000002764623,0.000009599717,6.076698e-7,0.0001047806],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00314781,"threshold_uncertainty_score":0.01053047,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0678600327954524,"score_gpt":0.4015528724213044,"score_spread":0.333692839625852,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}